Literature DB >> 24813517

Clinical implications and pathogenesis of esophageal remodeling in eosinophilic esophagitis.

Ikuo Hirano1, Seema S Aceves2.   

Abstract

In eosinophilic esophagitis (EoE), remodeling changes are manifest histologically in the epithelium and subepithelium where lamina propria fibrosis, expansion of the muscularis propria, and increased vascularity occur. The clinical symptoms and complications of EoE are largely consequences of esophageal remodeling. Available therapies have demonstrated variable ability to reverse existing remodeling changes of the esophagus. Systemic therapies have the potential of addressing subepithelial remodeling. Esophageal dilation remains a useful, adjunctive therapeutic maneuver in symptomatic adults with esophageal stricture. As novel treatments emerge, it is essential that therapeutic end points account for the fundamental contributions of esophageal remodeling to overall disease activity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Dysphagia; Endoscopy; Eosinophilic esophagitis; Esophagitis; Fibrosis; Gastroesophageal reflux disease; Remodeling

Mesh:

Year:  2014        PMID: 24813517      PMCID: PMC4127387          DOI: 10.1016/j.gtc.2014.02.015

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  73 in total

1.  Fluticasone and food allergen elimination reverse sub-epithelial fibrosis in children with eosinophilic esophagitis.

Authors:  Samer M A Abu-Sultaneh; Paul Durst; Virginia Maynard; Yoram Elitsur
Journal:  Dig Dis Sci       Date:  2010-05-11       Impact factor: 3.199

2.  Manometric features of eosinophilic esophagitis in esophageal pressure topography.

Authors:  S Roman; I Hirano; M A Kwiatek; N Gonsalves; J Chen; P J Kahrilas; J E Pandolfino
Journal:  Neurogastroenterol Motil       Date:  2010-11-23       Impact factor: 3.598

Review 3.  Relationships between eosinophilic inflammation, tissue remodeling, and fibrosis in eosinophilic esophagitis.

Authors:  Seema S Aceves; Steven J Ackerman
Journal:  Immunol Allergy Clin North Am       Date:  2009-02       Impact factor: 3.479

Review 4.  Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions.

Authors:  Takumi Kiwamoto; Norihito Kawasaki; James C Paulson; Bruce S Bochner
Journal:  Pharmacol Ther       Date:  2012-06-27       Impact factor: 12.310

5.  Working with the US Food and Drug Administration: progress and timelines in understanding and treating patients with eosinophilic esophagitis.

Authors:  Marc E Rothenberg; Seema Aceves; Peter A Bonis; Margaret H Collins; Nirmala Gonsalves; Sandeep K Gupta; Ikuo Hirano; Chris A Liacouras; Phil E Putnam; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Glenn T Furuta
Journal:  J Allergy Clin Immunol       Date:  2012-09       Impact factor: 10.793

6.  Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis.

Authors:  Carine Blanchard; Emily M Stucke; Karen Burwinkel; Julie M Caldwell; Margaret H Collins; Annette Ahrens; Bridget K Buckmeier; Sean C Jameson; Allison Greenberg; Ajay Kaul; James P Franciosi; Jonathan P Kushner; Lisa J Martin; Philip E Putnam; J Pablo Abonia; Suzanne I Wells; Marc E Rothenberg
Journal:  J Immunol       Date:  2010-03-05       Impact factor: 5.422

Review 7.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

8.  Thymic stromal lymphopoietin-elicited basophil responses promote eosinophilic esophagitis.

Authors:  Mario Noti; Elia D Tait Wojno; Brian S Kim; Mark C Siracusa; Paul R Giacomin; Meera G Nair; Alain J Benitez; Kathryn R Ruymann; Amanda B Muir; David A Hill; Kudakwashe R Chikwava; Amin E Moghaddam; Quentin J Sattentau; Aneesh Alex; Chao Zhou; Jennifer H Yearley; Paul Menard-Katcher; Masato Kubo; Kazushige Obata-Ninomiya; Hajime Karasuyama; Michael R Comeau; Terri Brown-Whitehorn; Rene de Waal Malefyt; Patrick M Sleiman; Hakon Hakonarson; Antonella Cianferoni; Gary W Falk; Mei-Lun Wang; Jonathan M Spergel; David Artis
Journal:  Nat Med       Date:  2013-07-21       Impact factor: 53.440

Review 9.  Emerging drugs for eosinophilic esophagitis.

Authors:  Emily Kern; Ikuo Hirano
Journal:  Expert Opin Emerg Drugs       Date:  2013-08-13       Impact factor: 4.191

10.  FGF9-induced proliferative response to eosinophilic inflammation in oesophagitis.

Authors:  D J Mulder; I Pacheco; D J Hurlbut; N Mak; G T Furuta; R J MacLeod; C J Justinich
Journal:  Gut       Date:  2008-10-31       Impact factor: 23.059

View more
  51 in total

Review 1.  Application of the Functional Lumen Imaging Probe to Esophageal Disorders.

Authors:  Dustin A Carlson; Ikuo Hirano
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

Review 2.  Biological therapies for eosinophilic gastrointestinal diseases.

Authors:  Joshua B Wechsler; Ikuo Hirano
Journal:  J Allergy Clin Immunol       Date:  2018-05-31       Impact factor: 10.793

Review 3.  White Paper AGA: Drug Development for Eosinophilic Esophagitis.

Authors:  Ikuo Hirano; Stuart Spechler; Glenn Furuta; Evan S Dellon
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03-22       Impact factor: 11.382

4.  Treating Eosinophilic Esophagitis in Patients With a Narrow-Caliber Esophagus.

Authors:  Evan S Dellon
Journal:  Gastroenterol Hepatol (N Y)       Date:  2016-09

Review 5.  Eosinophilic Esophagitis.

Authors:  Craig C Reed; Evan S Dellon
Journal:  Med Clin North Am       Date:  2018-11-01       Impact factor: 5.456

6.  A Randomized Controlled Comparison of Esophageal Clearance Times of Oral Budesonide Preparations.

Authors:  Jody N Hefner; Robin S Howard; Robert Massey; Miland Valencia; Derek J Stocker; Katherine Q Philla; Matthew D Goldman; Cade M Nylund; Steve B Min
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

7.  Therapy: Positioning of dilation in eosinophilic oesophagitis.

Authors:  Alex Straumann; Alain Schoepfer
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-03-02       Impact factor: 46.802

Review 8.  Functional Lumen Imaging Probe for the Management of Esophageal Disorders: Expert Review From the Clinical Practice Updates Committee of the AGA Institute.

Authors:  Ikuo Hirano; John E Pandolfino; Guy E Boeckxstaens
Journal:  Clin Gastroenterol Hepatol       Date:  2017-03       Impact factor: 11.382

9.  Control of inflammation decreases the need for subsequent esophageal dilation in patients with eosinophilic esophagitis.

Authors:  T M Runge; S Eluri; J T Woosley; N J Shaheen; E S Dellon
Journal:  Dis Esophagus       Date:  2017-07-01       Impact factor: 3.429

10.  Obtaining adequate lamina propria for subepithelial fibrosis evaluation in pediatric eosinophilic esophagitis.

Authors:  Jason Wang; Jason Y Park; Rong Huang; Rhonda F Souza; Stuart J Spechler; Edaire Cheng
Journal:  Gastrointest Endosc       Date:  2018-01-05       Impact factor: 9.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.